Skip to main content
Clinical Trials/JPRN-jRCT1050230049
JPRN-jRCT1050230049
Recruiting
未知

Observational study to evaluate the impact of heterogeneities of RAS/BRAF in tissue and ctDNA on the efficacy of anti EGFR antibody in advanced colorectal cancer - RAS-trace 2

Kozo Kataoka0 sites240 target enrollmentJune 24, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
colorectal cancer
Sponsor
Kozo Kataoka
Enrollment
240
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 24, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kozo Kataoka

Eligibility Criteria

Inclusion Criteria

  • 1\)Histologically proven for colorectal cancer
  • 2\)Clinical Stage IV or recurrent colorectal cancer for which more than 12 cycles of chemotherapy including anti\-EGFR therapy is planned.
  • 3\)measurable lesions according to RECIST ver1\.1
  • 4\)Presence of liver metastases
  • 5\) No previous history of chemotherapy and radiotherapy
  • 6\)Aged 20 years old and over
  • 7\)ECOG PS0\-1
  • 8\)Consent for blood exam for ctDNA analy
  • 9\)Written informed consen

Exclusion Criteria

  • 1\)Active other malignancies
  • 2\)Histologically confirmed for MMRD (MSI\-H or dMMR)
  • 3\)Pregnancy, possible pregnancy or breastfeeding
  • 4\)Severe pulmonary fibrosis or emphysema
  • 5\)Psychiatric disease
  • 6\)Patients requiring systemic steroid medication
  • 7\) Grade 2 or greater diarrhea or sensory neuropathy
  • 8\)Poorly controlled hypertension
  • 9\)History of severe heart disease, heart failure, unstable angina within 6 months or angina attack with 6 months
  • 10\) active COVID\-19 infection

Outcomes

Primary Outcomes

Not specified

Similar Trials